Skip to main content

Wi go tɔk bɔt Stej IV Breast Cancer ɛn aw fɔ trit am?

Wi go tɔk bɔt Stej IV Breast Cancer ɛn aw fɔ trit am?

We wi yɛri bɔt bɔdi kansa, wi kin rili sɔprayz. Ɛn we wi yɛri se na stej 4, dat min se di kansa dɔn skata to ɔda pat dɛn na di bɔdi, i kin mek wi fred mɔ ɛn mɔ. Dis na rili siriɔs tin. Bɔt wit dis advans mɛdikal sayɛns, bɔku tritmɛnt dɛn de we dɛn kin du na dis stej, we kin ɛp fɔ kɔntrol di sik ɛn mek pɔsin liv lɔng. So lɛ wi tɔk bɔt dis tide, fɔ fɛn simpul ansa to di kwɛstyɔn dɛn we yu gɛt na yu maynd.

Wetin rili na Stej IV?

Fɔ tɔk am simpul wan, stej 4 min se di kansa sɛl dɛn we bigin na di bɔdi dɔn spre tru di blɔd ɔ di limf vesel dɛn to ɔda pat dɛn na di bɔdi. dis spred dεn kכl am `Mεtastasis`. Di say dɛn we kansa kin pas dis kayn we na di bon dɛn, di bren, di lɔng dɛn, ɔ di liva .

Di impɔtant tin fɔ ɔndastand ya na dat di men gol fɔ tritmɛnt na dis stej nɔto fɔ mɛn di sik ɔltogɛda, bɔt fɔ kɔntrol aw di kansa de gro, ridyus di sayn dɛm, ɛn gi yu gud kwaliti layf fɔ as lɔng as yu ebul. Sɔm sik pipul dɛn kin liv fɔ bɔrku ia wit dis tritmɛnt. So, i impɔtant fɔ mek yu nɔ fred we yu yɛri bɔt dis pɔsibul, bɔt fɔ tek tɛm tɔk to yu dɔktɔ bɔt di tritmɛnt dɛn we de.

Wetin na di men tritmɛnt dɛn we pɔsin kin gɛt?

Insay stej 4, bikɔs di kansa dɔn skata to bɔku say dɛm, i nɔ kin izi fɔ gɛt saksesful rizɔlt wit tritmɛnt dɛm we de jɔs tɔch wan sayt, lɛk ɔpreshɔn ɔ redyushɔn tɛrapi. So, na dεn kin yus di sεstεmik tritmεnt dεm we de afekt di כl bכdi.

Kimotɛrapi

Bɔku tɛm, na di men tritmɛnt we dɛn kin gi na dis stej, na di kimotɛrapi. I de wok bay we i de kil di kansa sɛl dɛn we de sheb kwik kwik wan. Dis kin mek di kansa nɔ gro sloslo. Dɛn kin gi kemotɛrapi difrɛn we dɛn. Sɔntɛnde dɛn kin gi am as pils, bɔt bɔku tɛm dɛn kin gi am insay di bɛlɛ (tru wan vein) .

Dɛn nɔ kin de gi dis tritmɛnt ɔltɛm. Dɛn kin gi am bɔku saykl dɛn . Afta wan saykl dɔn, dɛn kin gi di bɔdi shɔt tɛm fɔ rɛst fɔ mek i wɛl. Na da tɛm de nɔmɔ di nɛks saykl kin bigin.

Ɔmon Tɛrapi

Dis tritmɛnt nɔ fayn fɔ ɔlman. I kin wok fayn pas ɔl pan uman dɛn we gɛt wan kayn kansa we dɛn kɔl ɔmon riseptɔ-pɔzitiv . dis min se di כmon dεm lεk εstrojen na dεn bכdi de mek di kεnsar sεl dεm gro. Tink bɔt dis we: ɔmon dɛn tan lɛk ki, ɛn di tin we de tek di kansa sɛl tan lɛk lɔk. We yu put di ki insay, di lɔk kin opin ɛn di kansa kin gro.

So wetin dɛn ɔmon tritmɛnt ya kin du na fɔ stɔp di prodyuz fɔ da ki (ɔmon), ɔ blok am fɔ mek i nɔ fit insay di lɔk. Di men kayn mɛrɛsin wae dɛn kin gi fɔ dis na:

  • ``Tamoksifen''.
  • Aromatase inhibitor (fɔ uman dɛn we dɔn pas 40 ia) - Ɛgzampul dɛn: Anastrozole (Arimidex), Exemestane (Aromasin) .
  • Drug dεm lεk `Fulvestrant (Faslodex)` we de blכk di כmon rεsεpכta dεm.

Sɔntɛnde, i kin fayn fɔ mek uman dɛn we nɔ rich di uman we dɔn pas yet fɔ gɛt ɔpreshɔn fɔ pul di ovaria, bikɔs na fayn we fɔ stɔp di ɔmon dɛn we de ɛp kansa fɔ gro.

Tɛrapi we dɛn de tɔk bɔt

Dis na tritmɛnt we nɔ tu nyu ɛn we rili wok. Bifo i pwɛl di sɛl dɛn we gɛt wɛlbɔdi lɛk kemotɛrapi, i de tɔch ɛn atak sɔm patikyula prɔtin ɔ jin dɛn we de na di kansa sɛl dɛn nɔmɔ . Dis kin mek i nɔ gɛt bɔku sayd ɛfɛkt dɛn.

כlmost 20% pan di uman dεm we gεt brεst kεnsar gεt tu mכch wan protin we dεn kכl `HER2`. Dis kin mek di kansa skata kwik kwik wan. Fɔ dɛn `HER2-positiv` kansa ya, dɛn kin gi drɔgs lɛk `Trastuzumab (Herceptin)`. i de stכp di `HER2` protin fכ wok εn i de kכntro di growth fכ di kεnsar sεl dεm.

Mɛmba se, stej 4 nɔ min se di tritmɛnt dɔn. Dis na tɛm fɔ pe atɛnshɔn pan tritmɛnt dɛm wae de ɛp fɔ kɔntrol di sik ɛn kip gud kwaliti layf.

Lɛ wi luk sɔm ɔda kayn tritmɛnt dɛm wae dɛn kin tɔk bɔt na di tebul wae de dɔŋ ya.

Targeted terapi tayp Gol ɛn di wok we yu fɔ du Yuz kes dɛn
CDK4/6 Inhibitɔ dɛn i de blok di protin dεm we dεn kכl CDK εn i de kכntro di kεnsar sεl dεm we de sheb. Fɔ ɛgzampul: Palbosiklib (Ibrans), Ribosiklib (Kisqali) . Fכ כmon rεsεptכr-pכzitiv εn HER2-nεgεtiv kεnsar dεm.
PARP Inhibitɔ dɛn tכgεt di PARP protin, we de εp di kεnsar sεl dεm fכ gro. Fɔ ɛgzampul: Olaparib (Lynparza) . fכ kεnsar dεm we HER2-nεgεtiv εn gεt BRCA jin mכtεshכn.
mTOR Inhibitɔ dɛn i de blכk di mTOR protin εn i de stכp di kεnsar sεl dεm we de gro εn spre. Fɔ ɛgzampul: Ɛvɛrimɔs (Afinitor) . Wit ɔmon tɛrapi fɔ sɔm kayn kansa.
Antibodi-drɔg kɔnjɔgɛt dɛn Wan kemo drɔg kin tay pan wan antibodi, we kin kɛr di mɛrɛsin go dairekt to di kansa sɛl ɛn pwɛl am. Fɔ ɛgzampul: Sacituzumab govitecan (Trodelvy) . Fɔ advans brɔst kansa.

Imyunotɛrapi

Dis na tritmɛnt bak we rili advans. Bifo yu gi yu drɔgs frɔm ɔdasay fɔ kil di kansa, i de mek yu yon imyun sistɛm ebul fɔ fɛn ɛn pwɛl di kansa sɛl dɛn. Sɔm kansa sɛl dɛn no aw fɔ ayd frɔm di imyun sistɛm. So dɛn drɔgs ya de mek dɛn we dɛn de ayd nɔ wok ɛn dɛn de mek di imyun sɛl dɛn no di kansa.

Ɔpreshɔn ɛn Redyushɔn

As wi bin dɔn tɔk, dɛn nɔ de yuz dɛn tin ya as di men tritmɛnt na dis stej. Bɔt if bad bad pen de na say usay di kansa dɔn skata, fɔ ɛgzampul na bon, dɛn kin gi redyushɔn tɛrapi fɔ kɔntrol di pen ɛn ɔda sayn dɛn . Dɔn bak, dɛn kin du ɔpreshɔn nɔmɔ if nid de fɔ kɔntrol ɛni prɔblɛm.

Ɔda impɔtant pɔynt dɛn

  • Sayd ɛfɛkt mɛnejɛmɛnt: Ɔl dɛn tritmɛnt ya kin gɛt sayd ɛfɛkt, lɛk fɔ nɔs, vɔmit, ɛn taya. Bɔt mɛrɛsin dɛn de fɔ mɛn dɛn. So tɛl yu dɔktɔ bɔt ɛni prɔblɛm we yu fil.
  • Klinik Trayal: Sɔntɛnde, yu kin ebul fɔ tek pat pan `Klinik Trayal`, we de tɛst nyu tritmɛnt dɛn we dɛn nɔ yuz yet bɔku bɔku wan. Dɛn tin ya kin gi yu di chans fɔ gɛt di bɛst tritmɛnt dɛn. Aks yu dɔktɔ bɔt dis bak.

Dis joyn nɔto wan we yu de go tru yu wan. Yu famili, padi dɛn, dɔktɔ dɛn, nɔs dɛn, ɛn di wan ol mɛdikal tim de wit yu. Gɛt dɛn sɔpɔt. Tɔk bɔt aw yu de fil. I go bi big trɛnk fɔ pas dis tranga tɛm.

Mɛsej we dɛn kin kɛr go na os

  • Stej IV brɔst kansa min se di kansa dɔn skata to ɔda pat dɛn na di bɔdi.
  • Di men gol fɔ tritmɛnt na dis stej nɔto fɔ mɛn di sik ɔltogɛda, bɔt fɔ kɔntrol di kansa, ridyus di sayn dɛm, ɛn ɛkstɛnd layf wit gud kwaliti layf.
  • Kimotɛrapi, ɔmon tɛrapi, targeted therapy, ɛn immunotherapy na di men we fɔ trit.
  • Yu dɔktɔ go disayd di tritmɛnt we go fayn fɔ yu bay di kayn we aw yu gɛt kansa (e.g., HER2-positiv ɔ hormone receptor-positive).
  • Mɛrɛsin dɛn de bak fɔ kɔntrol di sayd ɛfɛkt dɛn we yu kin gɛt frɔm di tritmɛnt, so tɔk to yu dɔktɔ bɔt ɛni prɔblɛm we yu go gɛt.
  • I rili impɔtant fɔ mek yu gɛt strɔng maynd ɛn aks fɔ sɔpɔt frɔm yu fambul ɛn di mɛdikal tim.

Brest kansa, Stej IV brɔst kansa, kansa tritmɛnt, kemotɛrapi, ɔmon tɛrapi, targeted therapy, Herceptin, uman dɛn wɛlbɔdi, kansa simptom dɛm
⚠️ Important: The medical articles and information on Nirogi Lanka are for general awareness only, and are by no means a substitute for professional medical advice, diagnosis, or treatment. For any medical problem you have, consult a qualified physician immediately.

💬 Comments (0)

No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.

Ad yu kɔmɛnt

Duya kɔlkul: 6 + 8 =
Wi go tɔk bɔt Stej IV Breast Cancer ɛn aw fɔ trit am?

Wi go tɔk bɔt Stej IV Breast Cancer ɛn aw fɔ trit am?

We wi yɛri bɔt bɔdi kansa, wi kin rili sɔprayz. Ɛn we wi yɛri se na stej 4, dat min se di kansa dɔn skata to ɔda pat dɛn na di bɔdi, i kin mek wi fred mɔ ɛn mɔ. Dis na rili siriɔs tin. Bɔt wit dis advans mɛdikal sayɛns, bɔku tritmɛnt dɛn de we dɛn kin du na dis stej, we kin ɛp fɔ kɔntrol di sik ɛn mek pɔsin liv lɔng. So lɛ wi tɔk bɔt dis tide, fɔ fɛn simpul ansa to di kwɛstyɔn dɛn we yu gɛt na yu maynd.

Wetin rili na Stej IV?

Fɔ tɔk am simpul wan, stej 4 min se di kansa sɛl dɛn we bigin na di bɔdi dɔn spre tru di blɔd ɔ di limf vesel dɛn to ɔda pat dɛn na di bɔdi. dis spred dεn kכl am `Mεtastasis`. Di say dɛn we kansa kin pas dis kayn we na di bon dɛn, di bren, di lɔng dɛn, ɔ di liva .

Di impɔtant tin fɔ ɔndastand ya na dat di men gol fɔ tritmɛnt na dis stej nɔto fɔ mɛn di sik ɔltogɛda, bɔt fɔ kɔntrol aw di kansa de gro, ridyus di sayn dɛm, ɛn gi yu gud kwaliti layf fɔ as lɔng as yu ebul. Sɔm sik pipul dɛn kin liv fɔ bɔrku ia wit dis tritmɛnt. So, i impɔtant fɔ mek yu nɔ fred we yu yɛri bɔt dis pɔsibul, bɔt fɔ tek tɛm tɔk to yu dɔktɔ bɔt di tritmɛnt dɛn we de.

Wetin na di men tritmɛnt dɛn we pɔsin kin gɛt?

Insay stej 4, bikɔs di kansa dɔn skata to bɔku say dɛm, i nɔ kin izi fɔ gɛt saksesful rizɔlt wit tritmɛnt dɛm we de jɔs tɔch wan sayt, lɛk ɔpreshɔn ɔ redyushɔn tɛrapi. So, na dεn kin yus di sεstεmik tritmεnt dεm we de afekt di כl bכdi.

Kimotɛrapi

Bɔku tɛm, na di men tritmɛnt we dɛn kin gi na dis stej, na di kimotɛrapi. I de wok bay we i de kil di kansa sɛl dɛn we de sheb kwik kwik wan. Dis kin mek di kansa nɔ gro sloslo. Dɛn kin gi kemotɛrapi difrɛn we dɛn. Sɔntɛnde dɛn kin gi am as pils, bɔt bɔku tɛm dɛn kin gi am insay di bɛlɛ (tru wan vein) .

Dɛn nɔ kin de gi dis tritmɛnt ɔltɛm. Dɛn kin gi am bɔku saykl dɛn . Afta wan saykl dɔn, dɛn kin gi di bɔdi shɔt tɛm fɔ rɛst fɔ mek i wɛl. Na da tɛm de nɔmɔ di nɛks saykl kin bigin.

Ɔmon Tɛrapi

Dis tritmɛnt nɔ fayn fɔ ɔlman. I kin wok fayn pas ɔl pan uman dɛn we gɛt wan kayn kansa we dɛn kɔl ɔmon riseptɔ-pɔzitiv . dis min se di כmon dεm lεk εstrojen na dεn bכdi de mek di kεnsar sεl dεm gro. Tink bɔt dis we: ɔmon dɛn tan lɛk ki, ɛn di tin we de tek di kansa sɛl tan lɛk lɔk. We yu put di ki insay, di lɔk kin opin ɛn di kansa kin gro.

So wetin dɛn ɔmon tritmɛnt ya kin du na fɔ stɔp di prodyuz fɔ da ki (ɔmon), ɔ blok am fɔ mek i nɔ fit insay di lɔk. Di men kayn mɛrɛsin wae dɛn kin gi fɔ dis na:

  • ``Tamoksifen''.
  • Aromatase inhibitor (fɔ uman dɛn we dɔn pas 40 ia) - Ɛgzampul dɛn: Anastrozole (Arimidex), Exemestane (Aromasin) .
  • Drug dεm lεk `Fulvestrant (Faslodex)` we de blכk di כmon rεsεpכta dεm.

Sɔntɛnde, i kin fayn fɔ mek uman dɛn we nɔ rich di uman we dɔn pas yet fɔ gɛt ɔpreshɔn fɔ pul di ovaria, bikɔs na fayn we fɔ stɔp di ɔmon dɛn we de ɛp kansa fɔ gro.

Tɛrapi we dɛn de tɔk bɔt

Dis na tritmɛnt we nɔ tu nyu ɛn we rili wok. Bifo i pwɛl di sɛl dɛn we gɛt wɛlbɔdi lɛk kemotɛrapi, i de tɔch ɛn atak sɔm patikyula prɔtin ɔ jin dɛn we de na di kansa sɛl dɛn nɔmɔ . Dis kin mek i nɔ gɛt bɔku sayd ɛfɛkt dɛn.

כlmost 20% pan di uman dεm we gεt brεst kεnsar gεt tu mכch wan protin we dεn kכl `HER2`. Dis kin mek di kansa skata kwik kwik wan. Fɔ dɛn `HER2-positiv` kansa ya, dɛn kin gi drɔgs lɛk `Trastuzumab (Herceptin)`. i de stכp di `HER2` protin fכ wok εn i de kכntro di growth fכ di kεnsar sεl dεm.

Mɛmba se, stej 4 nɔ min se di tritmɛnt dɔn. Dis na tɛm fɔ pe atɛnshɔn pan tritmɛnt dɛm wae de ɛp fɔ kɔntrol di sik ɛn kip gud kwaliti layf.

Lɛ wi luk sɔm ɔda kayn tritmɛnt dɛm wae dɛn kin tɔk bɔt na di tebul wae de dɔŋ ya.

Targeted terapi tayp Gol ɛn di wok we yu fɔ du Yuz kes dɛn
CDK4/6 Inhibitɔ dɛn i de blok di protin dεm we dεn kכl CDK εn i de kכntro di kεnsar sεl dεm we de sheb. Fɔ ɛgzampul: Palbosiklib (Ibrans), Ribosiklib (Kisqali) . Fכ כmon rεsεptכr-pכzitiv εn HER2-nεgεtiv kεnsar dεm.
PARP Inhibitɔ dɛn tכgεt di PARP protin, we de εp di kεnsar sεl dεm fכ gro. Fɔ ɛgzampul: Olaparib (Lynparza) . fכ kεnsar dεm we HER2-nεgεtiv εn gεt BRCA jin mכtεshכn.
mTOR Inhibitɔ dɛn i de blכk di mTOR protin εn i de stכp di kεnsar sεl dεm we de gro εn spre. Fɔ ɛgzampul: Ɛvɛrimɔs (Afinitor) . Wit ɔmon tɛrapi fɔ sɔm kayn kansa.
Antibodi-drɔg kɔnjɔgɛt dɛn Wan kemo drɔg kin tay pan wan antibodi, we kin kɛr di mɛrɛsin go dairekt to di kansa sɛl ɛn pwɛl am. Fɔ ɛgzampul: Sacituzumab govitecan (Trodelvy) . Fɔ advans brɔst kansa.

Imyunotɛrapi

Dis na tritmɛnt bak we rili advans. Bifo yu gi yu drɔgs frɔm ɔdasay fɔ kil di kansa, i de mek yu yon imyun sistɛm ebul fɔ fɛn ɛn pwɛl di kansa sɛl dɛn. Sɔm kansa sɛl dɛn no aw fɔ ayd frɔm di imyun sistɛm. So dɛn drɔgs ya de mek dɛn we dɛn de ayd nɔ wok ɛn dɛn de mek di imyun sɛl dɛn no di kansa.

Ɔpreshɔn ɛn Redyushɔn

As wi bin dɔn tɔk, dɛn nɔ de yuz dɛn tin ya as di men tritmɛnt na dis stej. Bɔt if bad bad pen de na say usay di kansa dɔn skata, fɔ ɛgzampul na bon, dɛn kin gi redyushɔn tɛrapi fɔ kɔntrol di pen ɛn ɔda sayn dɛn . Dɔn bak, dɛn kin du ɔpreshɔn nɔmɔ if nid de fɔ kɔntrol ɛni prɔblɛm.

Ɔda impɔtant pɔynt dɛn

  • Sayd ɛfɛkt mɛnejɛmɛnt: Ɔl dɛn tritmɛnt ya kin gɛt sayd ɛfɛkt, lɛk fɔ nɔs, vɔmit, ɛn taya. Bɔt mɛrɛsin dɛn de fɔ mɛn dɛn. So tɛl yu dɔktɔ bɔt ɛni prɔblɛm we yu fil.
  • Klinik Trayal: Sɔntɛnde, yu kin ebul fɔ tek pat pan `Klinik Trayal`, we de tɛst nyu tritmɛnt dɛn we dɛn nɔ yuz yet bɔku bɔku wan. Dɛn tin ya kin gi yu di chans fɔ gɛt di bɛst tritmɛnt dɛn. Aks yu dɔktɔ bɔt dis bak.

Dis joyn nɔto wan we yu de go tru yu wan. Yu famili, padi dɛn, dɔktɔ dɛn, nɔs dɛn, ɛn di wan ol mɛdikal tim de wit yu. Gɛt dɛn sɔpɔt. Tɔk bɔt aw yu de fil. I go bi big trɛnk fɔ pas dis tranga tɛm.

Mɛsej we dɛn kin kɛr go na os

  • Stej IV brɔst kansa min se di kansa dɔn skata to ɔda pat dɛn na di bɔdi.
  • Di men gol fɔ tritmɛnt na dis stej nɔto fɔ mɛn di sik ɔltogɛda, bɔt fɔ kɔntrol di kansa, ridyus di sayn dɛm, ɛn ɛkstɛnd layf wit gud kwaliti layf.
  • Kimotɛrapi, ɔmon tɛrapi, targeted therapy, ɛn immunotherapy na di men we fɔ trit.
  • Yu dɔktɔ go disayd di tritmɛnt we go fayn fɔ yu bay di kayn we aw yu gɛt kansa (e.g., HER2-positiv ɔ hormone receptor-positive).
  • Mɛrɛsin dɛn de bak fɔ kɔntrol di sayd ɛfɛkt dɛn we yu kin gɛt frɔm di tritmɛnt, so tɔk to yu dɔktɔ bɔt ɛni prɔblɛm we yu go gɛt.
  • I rili impɔtant fɔ mek yu gɛt strɔng maynd ɛn aks fɔ sɔpɔt frɔm yu fambul ɛn di mɛdikal tim.

Brest kansa, Stej IV brɔst kansa, kansa tritmɛnt, kemotɛrapi, ɔmon tɛrapi, targeted therapy, Herceptin, uman dɛn wɛlbɔdi, kansa simptom dɛm
⚠️ Important: The medical articles and information on Nirogi Lanka are for general awareness only, and are by no means a substitute for professional medical advice, diagnosis, or treatment. For any medical problem you have, consult a qualified physician immediately.

💬 Comments (0)

No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.

Ad yu kɔmɛnt

Duya kɔlkul: 6 + 8 =